NCT06046274 2024-04-30
GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer
Genmab
Phase 2 Withdrawn
Clinical Trials
5 trialsNCT05431582 2023-06-15
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT05419817 2023-02-27
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
University of Pittsburgh
Phase 2 Withdrawn
NCT04611139 2022-03-02
Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers
HonorHealth Research Institute
Phase 1 Withdrawn
NCT04197219 2020-11-05
Pembrolizumab With Axitinib in Recurrent Endometrial Cancer
Case Comprehensive Cancer Center
Phase 2 Withdrawn